- 3SBio reported its 2026 interim results, posting a revenue of RMB 4.53 billion and an adjusted operating net profit of RMB 1.44 billion, representing a 26.5% year-over-year increase.
- The company advanced its innovation pipeline by securing marketing approvals for three Class 1 innovative drugs, advancing five products to the New Drug Application stage, and driving global clinical trials for PF-08634404.
- 3SBio also expanded its multi-therapeutic portfolio across oncology, autoimmune diseases, and nephrology, while its Wind ESG rating was upgraded to "AA" for its sustainable development practices.
